Bill > SB112

This bill restricts the state of Montana from using state or federal funds to purchase opioid antagonists (medications used to reverse opioid overdoses) from companies that were involved in opioid-related settlements after June 30, 2025. Specifically, the bill prohibits purchasing these medications from entities that were parties to, or are affiliated with parties to, legal settlements related to the manufacture, sale, or distribution of prescription opioids. There are two key exceptions: first, existing state contracts for opioid antagonists executed before July 1, 2025, can be fulfilled, but these contracts cannot be renewed after that date; second, companies that agreed to provide opioid antagonists as part of settlements entered into before September 1, 2024, must continue to provide these medications until their settlement terms are complete. The bill defines "opioid antagonist" by referencing an existing definition in Montana state law (50-32-603), and it will become effective immediately upon passage and approval. The legislation is intended to be integrated into Title 18, Chapter 1, Part 1 of Montana's state legal code.

Health and Social Services

https://bills.legmt.gov/#/laws/bill/2/LC2083